Literature DB >> 2663144

Elimination of malignant clonogenic breast cancer cells from human bone marrow.

I C Anderson1, E J Shpall, D S Leslie, K Nustad, J Ugelstad, W P Peters, R C Bast.   

Abstract

Autologous bone marrow transplantation is a promising approach to the treatment of breast cancer but is at present limited to patients without bone marrow metastases. To eliminate malignant clonogenic breast cancer cells from normal human bone marrow, immunomagnetic separation has been combined with chemoseparation using 4-hydroperoxycyclophosphamide. Breast cancer cell lines have been mixed with a 10-fold excess of irradiated human bone marrow from normal donors. Mixtures have been incubated with a combination of five different monoclonal antibodies which bind to epithelial cell surface antigens of Mr 42,000, 55,000, 72,000, 200,000, and greater than 200,000. Antiglobulin coated microspheres which contained magnetite were added, and tumor cells were trapped in a magnetic field. Elimination of tumor cells from the decanted marrow was measured in a limiting dilution assay. Two treatments with antibody and microspheres permitted elimination of 2-4 logs of clonogenic breast cancer cells, depending upon the cell line studied. Similar treatment of nonirradiated normal marrow failed to affect levels of colony forming units-granulocyte-macrophage significantly. Use of immunomagnetic purging in combination with 4-hydroperoxycyclophosphamide eliminated up to 5 logs of tumor cells but reduced the recovery of colony forming units-granulocyte-macrophage. If prompt engraftment is observed following reinfusion of similarly treated marrow in phase I trials, these techniques should permit extension of autologous bone marrow transplantation to a larger population of breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2663144

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

2.  Cytokeratin profile of immunomagnetically separated epithelial subsets of the human mammary gland.

Authors:  S Dairkee; H W Heid
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-05       Impact factor: 2.416

3.  Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources.

Authors:  L Chen; M Pulsipher; D Chen; C Sieff; A Elias; H A Fine; D W Kufe
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

4.  Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.

Authors:  A Canada; L Herman; K Kidd; C Robertson; D Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7).

Authors:  H J Gross; B Verwer; D Houck; R A Hoffman; D Recktenwald
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

Review 6.  Stem-cell transplantation for the treatment of advanced solid tumors.

Authors:  Yago Nieto; Roy B Jones; Elizabeth J Shpall
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

7.  A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood.

Authors:  W Helfrich; R ten Poele; G J Meersma; N H Mulder; E G de Vries; L de Leij; E F Smit
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.